exit related costs of $
0.1
billion
•
Favorable changes in the fair value of securities of $
0.1
billion
MedTech segment income before tax includes:
•
Acquisition and integration related costs of $
1.0
billion primarily related to the acquisition of Shockwave
•
Acquired in-process research and development expense of $
0.5
billion from the V-Wave acquisition
•
A gain of $
0.2
billion related to the Acclarent divestiture
•
A Medical Device Regulation charge of $
0.2
billion
•
A restructuring related charge of $
0.2
billion
(4)
Innovative Medicine segment income before tax includes:
•
One-time COVID-19 Vaccine manufacturing exit related costs of $
0.7
billion
•
A restructuring related charge of $
0.5
billion
•
Unfavorable changes in the fair value of securities of $
0.4
billion
•
Favorable litigation related items of $
0.1
billion
•
Loss on divestiture of $
0.2
billion.
•
An intangible asset impairment charge of approximately $
0.2
billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.
MedTech segment income before tax includes:
•
Acquired in-process research and development expense of $
0.4
billion related to the Laminar acquisition in 2023
•
A restructuring related charge of $
0.3
billion
•
Acquisition and integration related costs of $
0.2
billion primarily related to the acquisition of Abiomed
•
A Medical Device Regulation charge of $
0.3
billion
•
Income from litigation settlements of $
0.1
billion
(5)
Innovative Medicine segment income before tax includes:
•
One-time COVID-19 Vaccine manufacturing exit related costs of $
1.5
billion
•
An intangible asset impairment charge of approximately $
0.8
billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS
•
Litigation expense of $
0.1
billion
•
Unfavorable changes in the fair value of securities of $
0.7
billion
•
A restructuring related charge of $
0.1
billion
MedTech segment income before tax includes:
•
Litigation expense of $
0.6
billion primarily for pelvic mesh related costs
•
A restructuring related charge of $
0.3
billion
•
Acquisition and integration related costs of $
0.3
billion primarily related to the acquisition of Abiomed
•
A Medical Device Regulation charge of $
0.3
billion
(6)
General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
(7)
Long-lived assets include property, plant and equipment, net for fiscal years 2024, and 2023 of $
20,518
and $
19,898
, respectively, and intangible assets and goodwill, net for fiscal years 2024 and 2023 of $
81,818
and $